Drug Type Monoclonal antibody |
Synonyms CMTX 101, CMTX-001, CMTX-101 |
Target |
Mechanism bacterial DNABII inhibitors |
Therapeutic Areas |
Inactive Indication- |
Originator Organization Clarametyx Biosciences, Inc.Startup |
Active Organization Clarametyx Biosciences, Inc.Startup |
Inactive Organization- |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
Regulation- |
Start Date17 Jan 2024 |
Sponsor / Collaborator Clarametyx Biosciences, Inc.Startup |
Start Date14 Nov 2022 |
Sponsor / Collaborator Clarametyx Biosciences, Inc.Startup |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Cystic Fibrosis | Phase 2 | US | Clarametyx Biosciences, Inc.Startup | 17 Jan 2024 |
Infectious Diseases | Phase 2 | US | Clarametyx Biosciences, Inc.Startup | 17 Jan 2024 |
Community-acquired bacterial pneumonia | Phase 1 | US | Clarametyx Biosciences, Inc.Startup | 14 Nov 2022 |
Study | Phase | Population | Analyzed Enrollment | Group | Results | Evaluation | Publication Date |
---|
No Data |